Siirry suoraan sisältöön
Mighty mTOR. Should we fight it to cure cancer?
Mighty mTOR. Should we fight it to cure cancer?
Tallenna

Mighty mTOR. Should we fight it to cure cancer?

Lue Adobe DRM-yhteensopivassa e-kirjojen lukuohjelmassaTämä e-kirja on kopiosuojattu Adobe DRM:llä, mikä vaikuttaa siihen, millä alustalla voit lukea kirjaa. Lue lisää
Essay from the year 2016 in the subject Medicine - Medical Frontiers and Special Areas, grade: A, The Chinese University of Hong Kong (School of Biomedical Sciences), course: Cancer and Inflammation, language: English, abstract: When thinking about signalling pathways involved in cancer, p53 and src usually come to mind first. However, with the genomics and metabolomics progress new pro- and anti-oncogenic mechanisms are described every day. And one signalling pathway stand out as the most promising candidate for research. It seems like mammalian target of rapamycin (mTOR) regulates everything . It is involved in a whole range crucial processes on cell and organism levels: cell cycle, glycolysis, lipogenesis, gene transcription and protein translation, autophagy and immune cells specialization. mTOR as serine/threonine protein kinase belongs to the phosphoinositide-3-kinaserelated family. Being a signalling kinase its mechanism of regulation is altering the protein s substrate recognition via phosphorylation.
ISBN
9783668239074
Kieli
englanti
Julkaisupäivä
10.6.2016
Kustantaja
GRIN Verlag
Formaatti
  • PDF - Adobe DRM
Lue e-kirjoja täällä
  • Lue e-kirja mobiililaitteella/tabletilla
  • Lukulaite
  • Tietokone